e-learning
resources
ERJ
2001
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary toxicity with mefloquine
Udry E., Bailly F., Dusmet M., Schnyder P., Lemoine R., Fitting J.W.
Source:
Eur Respir J 2001; 18: 890-892
Journal Issue:
November
Disease area:
Interstitial lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Udry E., Bailly F., Dusmet M., Schnyder P., Lemoine R., Fitting J.W.. Pulmonary toxicity with mefloquine. Eur Respir J 2001; 18: 890-892
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Severe respiratory infection: when is ICU mandatory?
Comment on: Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury
Related content which might interest you:
Acute lung injury as a possible adverse drug reaction related to gefitinib
Source: Eur Respir J 2002 Jan 01;22(1):179-181
Year: 2003
Sulphasalazine and lung toxicity
Source: Eur Respir J 2002; 19: 756-764
Year: 2002
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
Source: Eur Respir J 2001; 17: 1228-1235
Year: 2001
Lung disease induced by novel chemotherapeutic agents and biomolecules
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006
Statin-induced fibrotic nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 577-580
Year: 2002
A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis
Source: Eur Respir J 2011; 38: 1145-1150
Year: 2011
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
Early short-term versus prolonged low-dose methylprednisolone therapy in acute lung injury
Source: Eur Respir J 2009; 33: 634-645
Year: 2009
Chloroquine treatment of interstitial lung diseases in children
Source: Eur Respir J 2004; 24: Suppl. 48, 717s
Year: 2004
Adverse pulmonary vascular effects of high dose tricyclic antidepressants: acute and chronic animal studies
Source: Eur Respir J 2002; 20: 344-352
Year: 2002
Desferrioxamine attenuates minor lung injury following surgical acute liver failure
Source: Eur Respir J 2009; 33: 1429-1436
Year: 2009
Effect of prior statin therapy on capillary permeability in the lungs after cardiac or vascular surgery
Source: Eur Respir J 2006; 27: 1026-1032
Year: 2006
Gemcitabine induced pulmonary toxicity with late oncet
Source: Eur Respir J 2006; 28: Suppl. 50, 382s
Year: 2006
To treat or not to treat with corticosteroids radiation induced pneumonitis
Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases
Year: 2013
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Effectiveness of treatment and correction of side effects in pulmonary MDR/XDR TB patients with concomitant liver injury
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Side-effects of antituberculosis drug treatment in patients with chronic renal failure
Source: Eur Respir J 2002; 20: 440-443
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept